Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -118.15% is 47% above its 5-year average of -221.92%, near the high end of its 5-year range (-493.33%–-75.08%).
14.47% above its 12-month average of -138.13%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -32.53%.
RETURN ON ASSETS (ROA)
-118.15%
RETURN ON ASSETS (ROA) AVG TTM
-138.13%
RETURN ON ASSETS (ROA) AVG 3Y
-224.99%
RETURN ON ASSETS (ROA) AVG 5Y
-221.92%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+14.47%
CURRENT VS 3Y AVG
+47.49%
CURRENT VS 5Y AVG
+46.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.14%
median of 562 covered companies
CURRENT VS SECTOR MEDIAN
-319.79%
vs the sector median at left
MiNK Therapeutics, Inc.
Market Cap
$58.91M
Return on Assets (ROA)
-118.15%
TTM Avg
-138.13%
3Y Avg
-224.99%
5Y Avg
-221.92%
Market Cap
$58.83M
Return on Assets (ROA)
-48.49%
TTM Avg
-50.18%
3Y Avg
-39.97%
5Y Avg
-38.29%
Market Cap
$59.97M
Return on Assets (ROA)
-66.80%
TTM Avg
-56.95%
3Y Avg
-50.95%
5Y Avg
-40.99%
Market Cap
$58.97M
Return on Assets (ROA)
-128.88%
TTM Avg
-89.84%
3Y Avg
-89.26%
5Y Avg
-80.42%
Market Cap
$58.66M
Return on Assets (ROA)
-37.05%
TTM Avg
-34.36%
3Y Avg
-41.63%
5Y Avg
-37.74%
Market Cap
$56.65M
Return on Assets (ROA)
-54.01%
TTM Avg
-81.00%
3Y Avg
-93.15%
5Y Avg
-65.68%
Market Cap
$62.78M
Return on Assets (ROA)
-5.05%
TTM Avg
-7.03%
3Y Avg
-4.31%
5Y Avg
-4.67%
Market Cap
$55.94M
Return on Assets (ROA)
-98.94%
TTM Avg
-57.19%
3Y Avg
-57.75%
5Y Avg
-128.29%
Market Cap
$65.26M
Return on Assets (ROA)
-44.47%
TTM Avg
-42.63%
3Y Avg
-230.85%
5Y Avg
-167.04%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | $58.91M | -118.15% | -138.13% | -224.99% | -221.92% |
| Aldeyra The (ALDX)vs › | $58.83M | -48.49% | -50.18% | -39.97% | -38.29% |
| Adicet Bio, Inc. (ACET)vs › | $59.97M | -66.80% | -56.95% | -50.95% | -40.99% |
| Fractyl Health, Inc. (GUTS)vs › | $58.97M | -128.88% | -89.84% | -89.26% | -80.42% |
| Boundless Bio, Inc. (BOLD)vs › | $58.66M | -37.05% | -34.36% | -41.63% | -37.74% |
| Spectral AI, Inc. (MDAI)vs › | $56.65M | -54.01% | -81.00% | -93.15% | -65.68% |
| InterCure Ltd. (INCR)vs › | $62.78M | -5.05% | -7.03% | -4.31% | -4.67% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $55.94M | -98.94% | -57.19% | -57.75% | -128.29% |
| Kalaris Therapeutics Inc (KLRS)vs › | $65.26M | -44.47% | -42.63% | -230.85% | -167.04% |
| Alps Group Inc (ALPS)vs › | $64.06M | -39.17% | -30.96% | -31.81% | -21.33% |
ROA
-118.2%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -87.75% |
| 2024-12-31 | -188.52% |
| 2023-12-31 | -493.33% |
| 2022-12-31 | -130.36% |
| 2021-12-31 | -75.08% |
| 2020-12-31 | -356.49% |
| 2019-12-31 | -1818.46% |
